Journal
FRONTIERS IN IMMUNOLOGY
Volume 13, Issue -, Pages -Publisher
FRONTIERS MEDIA SA
DOI: 10.3389/fimmu.2022.913215
Keywords
CD16a; NK cells; ADCC; monoclonal antibodies; cell therapy
Categories
Funding
- INCA/DGOS PRT-K program [2021-014]
- MUSE (Montpellier Universite d'Excellence
- MRT
- Investissements d'avenir Grant LabEx MAbImprove [ANR-10-LABX-53]
Ask authors/readers for more resources
This review provides an overview of the latest strategies employed to improve antibody-dependent NK cell cytotoxicity, by enhancing the biological function of CD16a receptor.
Antibody-dependent cell-mediated cytotoxicity (ADCC) is a potent cytotoxic mechanism that is mainly mediated in humans by natural killer (NK) cells. ADCC mediates the clinical benefit of several widely used cytolytic monoclonal antibodies (mAbs), and increasing its efficacy would improve cancer immunotherapy. CD16a is a receptor for the Fc portion of IgGs and is responsible to trigger NK cell-mediated ADCC. The knowledge of the mechanism of action of CD16a gave rise to several strategies to improve ADCC, by working on either the mAbs or the NK cell. In this review, we give an overview of CD16a biology and describe the latest strategies employed to improve antibody-dependent NK cell cytotoxicity.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
